Literature DB >> 27855957

Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy.

Taylor P Kohn1, Matthew R Louis1, Stephen M Pickett2, Mark C Lindgren3, Jaden R Kohn1, Alexander W Pastuszak4, Larry I Lipshultz5.   

Abstract

OBJECTIVE: To determine factors that influence sperm recovery after T-associated infertility.
DESIGN: Clinical retrospective study.
SETTING: Academic male-infertility urology clinic. PATIENT(S): Sixty-six men who presented with infertility after T use. INTERVENTION(S): T cessation and combination high-dose hCG and selective estrogen modulator (SERM) therapy. MAIN OUTCOME MEASURE(S): Whether patients successfully achieved or failed to achieve a total motile count (TMC) of greater than 5 million sperm within 12 months of T cessation and initiation of therapy. RESULT(S): A TMC of greater than 5 million sperm was achieved by 46 men (70%). Both increased age and duration of T use directly correlated with time to sperm recovery at both 6 and 12 months of hCG/SERM therapy. Age more consistently limited sperm recovery, while duration of T use had less influence at 12 months than at 6 months. Only 64.8% of azoospermic men achieved a TMC greater than 5 million sperm at 12 months, compared with 91.7% of cryptozoospermic men, yet this did not predict a failure of sperm recovery. CONCLUSION(S): Increasing age and duration of T use significantly reduce the likelihood of recovery of sperm in the ejaculate, based on a criterion of a TMC of 5 million sperm, at 6 and 12 months. Physicians should be cautious in pursuing long-term T therapy, particularly in men who still desire fertility. Using these findings, physicians can counsel men regarding the likelihood of recovery of sperm at 6 and 12 months.
Copyright © 2016 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Infertility; azoospermia; human chorionic gonadotropin; sperm; spermatogenesis-blocking agents; testosterone

Mesh:

Substances:

Year:  2016        PMID: 27855957      PMCID: PMC5292276          DOI: 10.1016/j.fertnstert.2016.10.004

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  24 in total

1.  Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey.

Authors:  John B McKinlay; Carol L Link
Journal:  Eur Urol       Date:  2007-03-19       Impact factor: 20.096

2.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

3.  Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies. World Health Organization Task force on Methods for The Regulations of Male Fertility.

Authors: 
Journal:  Int J Androl       Date:  1995-06

4.  Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens.

Authors:  Lam P Ly; Peter Y Liu; David J Handelsman
Journal:  Hum Reprod       Date:  2005-04-28       Impact factor: 6.918

5.  Testosterone suppression of the HPT axis.

Authors:  J H MacIndoe; P J Perry; W R Yates; T L Holman; V L Ellingrod; S D Scott
Journal:  J Investig Med       Date:  1997-10       Impact factor: 2.895

6.  Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Peter D Christenson; David J Handelsman; Christina Wang
Journal:  Lancet       Date:  2006-04-29       Impact factor: 79.321

7.  Contraceptive efficacy of a depot progestin and androgen combination in men.

Authors:  Leo Turner; Ann J Conway; Mark Jimenez; Peter Y Liu; Elise Forbes; Robert I McLachlan; David J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

8.  Vasectomy reversal outcomes in men previously on testosterone supplementation therapy.

Authors:  Robert M Coward; Douglas A Mata; Ryan P Smith; Jason R Kovac; Larry I Lipshultz
Journal:  Urology       Date:  2014-10-11       Impact factor: 2.649

9.  Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin.

Authors:  Dev Kumar Menon
Journal:  Fertil Steril       Date:  2003-06       Impact factor: 7.329

Review 10.  Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use.

Authors:  J Abram McBride; Robert M Coward
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285

View more
  12 in total

Review 1.  Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.

Authors:  Zachary J Solomon; Jorge Rivera Mirabal; Daniel J Mazur; Taylor P Kohn; Larry I Lipshultz; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2018-11-30

2.  Azoospermia With Testosterone Therapy Despite Concomitant Intramuscular Human Chorionic Gonadotropin: NYU Case of the Month, July 2018.

Authors:  Bobby Najari
Journal:  Rev Urol       Date:  2018

3.  Comparison of the effect of combined therapy of HCG ampule and letrozole tablet with each method separately on the spermogram parameters in the obese men with idiopathic infertility: a clinical trial.

Authors:  Yadollah Ahmadi-Asrbadr; Mahdi Hemmati-Ghavshough; Navid Khanzadeh; Fereshteh Ansari; Mohsen Mohammad-Rahimi
Journal:  Am J Clin Exp Urol       Date:  2022-08-15

Review 4.  Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS).

Authors:  Ankit Desai; Musaab Yassin; Axel Cayetano; Tharu Tharakan; Channa N Jayasena; Suks Minhas
Journal:  Ther Adv Urol       Date:  2022-06-26

Review 5.  Infertility in the Aging Male.

Authors:  Daniel J Mazur; Larry I Lipshultz
Journal:  Curr Urol Rep       Date:  2018-05-17       Impact factor: 3.092

6.  The Dynamic Transcriptional Cell Atlas of Testis Development during Human Puberty.

Authors:  Jingtao Guo; Xichen Nie; Maria Giebler; Hana Mlcochova; Yueqi Wang; Edward J Grow; Robin Kim; Melissa Tharmalingam; Gabriele Matilionyte; Cecilia Lindskog; Douglas T Carrell; Rod T Mitchell; Anne Goriely; James M Hotaling; Bradley R Cairns
Journal:  Cell Stem Cell       Date:  2020-01-09       Impact factor: 24.633

Review 7.  Frontiers in hormone therapy for male infertility.

Authors:  Iyad Khourdaji; Haerin Lee; Ryan P Smith
Journal:  Transl Androl Urol       Date:  2018-07

8.  Human Chorionic Gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone > 300 ng/dL.

Authors:  Vinayak Madhusoodanan; Premal Patel; Thiago Fernandes Negris Lima; Jabez Gondokusumo; Eric Lo; Nannan Thirumavalavan; Larry I Lipshultz; Ranjith Ramasamy
Journal:  Int Braz J Urol       Date:  2019 Sep-Oct       Impact factor: 3.050

Review 9.  Vasectomy reversal: decision making and technical innovations.

Authors:  E Will Kirby; Mark Hockenberry; Larry I Lipshultz
Journal:  Transl Androl Urol       Date:  2017-08

Review 10.  Testosterone Is a Contraceptive and Should Not Be Used in Men Who Desire Fertility.

Authors:  Amir Shahreza Patel; Joon Yau Leong; Libert Ramos; Ranjith Ramasamy
Journal:  World J Mens Health       Date:  2018-10-10       Impact factor: 5.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.